已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia

恩替卡韦 替诺福韦-阿拉芬酰胺 医学 肝细胞癌 内科学 胃肠病学 临床终点 不利影响 乙型肝炎 肝硬化 HBeAg 乙型肝炎病毒 病毒载量 拉米夫定 临床试验 免疫学 病毒 乙型肝炎表面抗原 抗逆转录病毒疗法 人类免疫缺陷病毒(HIV)
作者
Zhong‐Bin Li,Le Li,Xiao‐Xia Niu,Shunpeng Chen,Yiming Fu,Chunyan Wang,Yan Liu,Qing Shao,Guofeng Chen,Dong Ji
出处
期刊:Liver International [Wiley]
卷期号:41 (6): 1254-1264 被引量:59
标识
DOI:10.1111/liv.14786
摘要

Abstract Background and Aims About 20% of patients receiving nucleos(t)ide analogues treatment experienced low‐level viraemia (LLV), which is associated with progression of liver fibrosis and high risk of hepatocellular carcinoma. We aimed to evaluate the effectiveness and safety of switching from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in ETV‐treated patients with LLV. Methods In this prospective study, ETV‐treated patients with LLV, presented to our hospital from December 2018 to October 2019, were enrolled. Switching to TAF or continuing ETV was given. The primary effectiveness endpoint was complete virological response (CVR) at 24 weeks, and the safety endpoint was the first occurrence of any clinical adverse event during the treatment. Results Totally, 211 patients were recruited and propensity score matching (PSM) generated 75 patients in either TAF or ETV group. After PSM, baseline characteristics were balanced in two groups. After 24‐week treatment, the CVR and ALT normalization in TAF group were 62.7% and 47.6%, which were higher than 9.3% and 10.5% in ETV group (OR 16.4, 95% CI 6.6‐40.0, P < .001) respectively. Subgroup analysis showed that switching to TAF achieved favours CVR regardless of the status of sex, age, CHB family history, HBV DNA, HBeAg and cirrhosis, whereas alcohol consumption and diabetes mellitus might compromise the CVR of switching to TAF. Both therapies were well tolerated and had satisfying renal safety. Conclusions For ETV‐treated patients with LLV, switching to TAF is safe enough and superior compared with continuing ETV monotherapy regarding both virological and biochemical benefits.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
啊锐完成签到,获得积分0
刚刚
dax大雄完成签到 ,获得积分10
1秒前
小先发布了新的文献求助10
2秒前
3秒前
4秒前
Zzyj完成签到 ,获得积分10
4秒前
7秒前
机智以筠发布了新的文献求助10
8秒前
wewe发布了新的文献求助10
8秒前
10秒前
10秒前
Jack发布了新的文献求助10
12秒前
称心板凳完成签到,获得积分10
13秒前
CipherSage应助南烛采纳,获得10
15秒前
飞快的小懒虫完成签到,获得积分10
15秒前
苗条凡发布了新的文献求助10
15秒前
16秒前
368DFS发布了新的文献求助20
19秒前
20秒前
20秒前
23秒前
追寻依波完成签到,获得积分10
24秒前
27秒前
粥没想得甜完成签到,获得积分10
29秒前
孤傲的静脉完成签到,获得积分10
29秒前
Jack完成签到,获得积分10
30秒前
俏皮碧玉完成签到,获得积分10
31秒前
33秒前
长尾巴的人类完成签到,获得积分10
33秒前
33秒前
36秒前
大模型应助苗条凡采纳,获得10
38秒前
老迟到的羊完成签到 ,获得积分10
39秒前
南烛发布了新的文献求助10
40秒前
41秒前
玉一一发布了新的文献求助10
43秒前
cici完成签到,获得积分20
44秒前
45秒前
52秒前
倪斯芮发布了新的文献求助10
52秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 2000
Digital Twins of Advanced Materials Processing 2000
晋绥日报合订本24册(影印本1986年)【1940年9月–1949年5月】 1000
Social Cognition: Understanding People and Events 1000
Polymorphism and polytypism in crystals 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6033822
求助须知:如何正确求助?哪些是违规求助? 7731156
关于积分的说明 16204780
捐赠科研通 5180456
什么是DOI,文献DOI怎么找? 2772333
邀请新用户注册赠送积分活动 1755569
关于科研通互助平台的介绍 1640360